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Abstract
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In the design of engineered tissues, guided balance of biomaterial degeneration with tissue synthesis
offers refined control of construct development. The objective of this study was to develop a
mathematical model that describes the steady state metabolism of extracellular matrix molecules
(ECM: glycosaminoglycan and collagen) in an engineered cartilage construct taking into account
localized environmental changes that may arise because of the application of growth factors. The
variable effects of growth factors were incorporated in the form of random noise rather than the
difference in rates of synthesis and catabolism. Thus, the frequency of ECM accumulation for each
matrix molecule in the steady state under the random influence of growth factor was produced relative
to the matrix carrying capacity. Published synthesis-rate time constants and steady state ECM
conditions from chondrocyte-polymer scaffold composites provided both input and validation for
the model. Although the presence of growth factors in the presented system dynamics were
considered randomized, the results described a positive feedback or promotional ECM synthesis at
low levels of growth factors. While a negative feedback or inhibition of ECM synthesis was
characterized at higher levels of growth factors. This transition phenomenon is based on a comparison
with the results of a steady state condition in the form of a deterministic model and supports previous
reports of guided accumulation in musculoskeletal, connective, and neuronal tissues.
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INTRODUCTION
In the design of engineered tissues, balancing the processes of biomaterial degeneration with
tissue synthesis is critical during construct development. The combination of these two
processes represents the efflux and influx of materials that maintain the biological and
mechanical health of the dynamic composite. Cell–polymer constructs as used in engineered
cartilage, for example, consist of cells seeded on scaffolds of biodegradable polymers. The
scaffolds typically take the form of meshes, foams, or fleeces, and once seeded with cells can
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be cultured in vitro in a bioreactor or static culture,7,9,27 or in vivo in an animal model.3
Synthetic scaffolds degrade passively in culture, as the cells proliferate and assemble an
extracellular matrix (ECM), which in turn replace the scaffold. The major biomolecules within
the neotissue are: structural proteins, specialized proteins, and proteoglycans. Structural
proteins consist of collagen and elastin, specialized proteins consist of fibrillin, fibronectin,
and laminin, and proteoglycans are a core protein to which is attached to the long chains of
repeating disaccharide units termed as glycosaminoglycans (GAG).
In addition to structural support, ECM also acts as a reservoir of growth factors and cytokines,
such as IGF-1 (insulin like growth factor), TGF-β (transforming growth factor), and IL-1
(interleukin), respectively.1 Meaney Murray et al.20 observed that a number of selective
growth factors could remarkably increase the collagen production in ECM. Both in vivo and
in vitro experiments show that some growth factors enhance the production of biomolecules
and some inhibit it.6,28,32,33
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The degeneration and synthesis processes are spatially complementary. Over time the cells
deposit and remodel proteins to assume the space of the degrading polymer scaffold. Much of
the tissue engineering literature is focused on the processes of scaffold degradation and ECM
synthesis through empirical characterizations. There are a few published relationships,
however, that quantify the mechanistic factors behind the transient composition of these
constructs.24 A basis for biosynthesis kinetics can also be drawn from native tissue
research5,10 and the application of quantitative concepts to cartilage metabolism.13,14
Balancing the timing of the degradative and synthetic processes through a cellular feedback
perspective is critical to understanding the composite construct viability.
Buschmann et al.4 have reported on the study of engineering cartilage that there exists a strong
negative correlation between GAG molecules deposition and its synthesis rate. A similar type
of result has been obtained by Handley and Lowther11 in chondrocyte culture. A mathematical
model for native proteoglycan synthesis was described by Hascall et al.13,14 and restated by
Wilson et al.36 for application to engineered cartilage in which:

{

d (ECM)
= k0 (ECM)SS − (ECM)
dt

}

(1)

where, k0 is a rate constant and the subscript SS denotes the steady state condition (long-term,
“mature” engineered tissue at t → ∞ and d(ECM)/dt = 0). Equation (1) then implies:
(ECM)t = (ECM)SS 1 − e

−k0t

(2)
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In this model, specific interactions between the chondrocytes and ECM molecules are
addressed as rate constants. The steady state condition is assumed to be a ratio of matrix
synthesis and catabolism rates which are indeed influenced by metabolic mediators such as
growth factors.13 However, the variation in growth factor influence is not stated as a
mathematical function, only as a defined rate comparison.
The present article deals with the deposition of ECM molecules in Cell–polymer constructs.
The main objective of this paper is to describe deterministic and stochastic models which
characterize the steady state accumulation of different ECM molecules in a theoretical
engineered cartilage construct. The stochastic model development incorporates localized
environment changes that may arise due to the application of growth factors relative to the
baseline steady state condition and ECM carrying capacity. Here, the effects of growth factors
were incorporated in the form of random noise within the model system. This mathematical
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model explores a potential mechanism behind the functional characteristics of growth factors
within the Cell–polymer construct.
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MATERIALS AND METHODS
Model I: Deterministic Model without Growth Factor Variability
Initially, a deterministic model is developed that describes the accumulation of ECM molecules
of either primary component (GAG or collagen) in a Cell–polymer construct. In this theoretical
arrangement, it is assumed that accumulation of GAG and collagen are independent. This
assumption is based on a presumed scaffold cell seeding scenario such that a combination of
responses to growth factors, from isolated chondrocytes and chondrocytes in their ECM, would
lead to overall independent collagen and GAG metabolism.21 In addition, a steady state
condition can be achieved in the long-term similar to Eq (2) because of metabolic mediators
such as “growth factors.13 The formulation of this ECM dynamics model, on the basis of a
logistic scheme, is:
d (ECM)
(ECM)
= λ ′0(ECM) 1 −
dt
K0

(3)
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where λ′0 in a Cell–polymer construct. K0 is the carrying capacity for the specific ECM
molecule and is drawn from population dynamics as an analogue to the maximized steady state
condition.22 The dimensionless form of the modeled system (3) is:
dω
= λ0ω (1 − ω )
dτ

(4)

where,
ECM = K 0ω
t = K 0τ ,

(5)

λ0 = λ ′0 K 0

The general solution to Eq (4) is:
ω=

λ τ
ce 0
λ τ
1 + ce 0

(6)
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where, the arbitrary constant, c, can be obtained from the initial condition (τ = 0; ω = ω0), such
that:
c=

ω0
≈ ω0,
1 − ω0

as ω0 ≪ 1

(7)

At the steady state condition, τ → ∞ and then ω → 1. Therefore, the solution for GAG molecule
accumulation within the ECM is then characterized as:

(

λ τ
c1e 1
GAGτ = K 1
λ τ
1+c e 1
1

)

Concomitantly, the solution for collagen molecule accumulation is:
Ann Biomed Eng. Author manuscript; available in PMC 2006 March 17.
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(

λ τ
c2e 2
Collagenτ = K 2
λ τ
1+c e 2
2

)

(9)

where, K1, K2 are the carrying capacities within the construct, λ1, λ2 are the growth rates, and
c1, c2 are the ar- bitrary constants of GAG and collagen molecules, respectively. These
parameters can be evaluated by using the initial condition in Eq (7) and applied to long-term,
“maturing” engineered cartilage at τ = 0 → ∞, or inferred from published literature.
Thus, the steady state values for GAG and collagen molecules (when ω → 1) are the carrying
capacities, K1 and K2, respectively. This steady state analogue is assumed similar to that
presented by Hascall et al. as a constant ECM quantity defined by the rate of matrix synthesis
per a catabolism proportionality constant.13 Actual carrying capacity values are assumed fixed
and dependent upon a specific level of growth factor such that d(ECM)/dt = 0. Finally, the total
construct mass during steady state metabolism, M∞ which would include the cellular-mass,
MCell, and remaining scaffold components, is then:
M ∞ = M Cell + K 1 + K 2 + Limτ →∞(Scaffold)initiale

−k2τ

(10)
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where the scaffold degradation dynamics are assumed to follow first order decay kinetics
described by Rodriguez31 and applied to engineered tissue in Wilson et al.36
Model II: Stochastic Model with Growth Factor Variability
In the metabolism of ECM, the anabolic effects of IGF-1 and TGF-β are in contrast with
catabolism because of IL-1. We now extend the anabolic/catabolic interplay into the dynamics
of ECM molecule deposition as random fluctuations in the form of Gaussian white noise. This
approach enhances the dynamics described in Model I (Eq (3)) to include growth factor
variability. The initial model then becomes:

{

}

d (ECM)
(ECM)
= λ ′0 + ρ0′η (t ) (ECM) 1 −
dt
K0

(11)

or in dimensionless form, from Eq (5):

{

}

dω
= λ0 + ρ0η (τ ) ω (1 − ω )
dτ

(12)
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Where, η (τ) is the Gaussian white noise and ρ0 = ρ′0K0 > 0 is the concentration of growth
factor as an additional influence on the dynamics of matrix synthesis. This formulation does
not account for the fractional content of the active versus inactive forms of the growth factors.
Using a replacement term, which follows directly from the interpretation of the integral of η
(τ):8
dW (τ ) = W (τ + dτ ) − W (τ ) = η (τ )dτ

(13)

dW (τ ) ~ N (0, dτ )

(14)

where,

such that, N (μ; σ ) is a Normal distribution with mean, μ, and standard deviation, σ . Equation
(12) can then be rewritten as:
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dω = λ0ω (1 − ω )dτ + ρ0ω (1 − ω )dW

(15)
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The corresponding probabilistic distribution of the matrix molecules can be described via the
Fokker–Planck (FP) equation as:8,25
∂ P (ω , τ )
∂
= −
λ ω (1 − ω )P (ω , τ )
∂τ
∂ω 0
1 ∂2
+
ρ ω (1 − ω ) 2P (ω , τ )
2 ∂ω 2 0

{

}

(16)

where, P(ω τ) is the probability density function (PDF) of ECM deposition at time τ.
The growth factor concentration coefficient, ρ0 is assumed to be increasing as the matrix
molecules within the construct are increasing. Therefore, we assume,
ℜ0
ρ0 =
1−ω

(17)

where, ℜ0 is the level of growth factor randomly influencing an ECM component.
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At the steady state, the PDF of ECM deposition P∞(ω) is proportional to:30
2

ω

( )

λ0
−1
2λ0
ℜ2
0
exp −
ω
ℜ2
0

{ }

(18)

where,

∫01P∞(ω)dω = 1

(19)

Therefore, the frequency of GAG accumulation in engineered cartilage, which is known to be
dependent upon the competing rates of synthesis and catabolism at the steady state condition
because of a baseline growth factor level, are now extended to include the random influence
of growth factors:
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(
(

P∞(GAG) = C1

{

() )
)}

GAGSS

K1

2λ1 GAGSS
× exp −
K1
ℜ2
1

2

λ1
−1
ℜ2
1

(20)

The probabilistic density function for collagen is similar:

P∞(Collagen) = C2

{

(

(

CollagenSS

K2

2λ2 CollagenSS
× exp −
K2
ℜ2
2

)}

() )
2

λ2
−1
ℜ2
2
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where, ℜ1, ℜ2 are the levels of growth factor with respect to GAG and collagen molecule
synthesis, respectively, and C1, C2 are the constants of the proportionalities obtained by
applying Eq (19).
GAG

Now, let us consider dimensionless forms on the basis of the carrying capacities, X = K ,
1
Collagen

and Y =

K2

, where the total matrix molecules (Z) within the construct can be represented

by a linear relationship:
Z = X +Y

(22)

The probability density function for the total matrix molecules can then be represented by

{

} ∫xz=0+Δz f x(x)∫yz+=Δzz−−x x f y( y)dydx

P z < Z < z + Δz =

(23)

where,
2
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f x ( x ) = C1 x

( )

λ1
−1
2λ1
ℜ2
1
exp −
x and
ℜ2
1
2

f y ( y ) = C2 y

{ }

( )

λ2
−1
2λ2
ℜ2
2
exp −
y
ℜ2
2

{ }

(24)

(25)

are the density functions of X and Y , respectively. Hence, the probability density function of
Z is:
f z (z ) =

∫0z f x(x) f y(z − x)dx

(26)

that implies,
f z ( z ) = C 1C 2 × B
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{(
1,

×2 F 2

2λ1
ℜ2
1

(

2λ2
ℜ2
2

− 1; 2

(

− 1,

2λ1
ℜ2
1

)

−1

λ1
λ2
−
z
2
ℜ2
ℜ
1
2

)

}

λ1
λ2
+
2
ℜ1 ℜ2
2
2λ1 2λ2
+
−3
2λ2
ℜ2
ℜ2
1
2
×z
× exp − 2
z
ℜ2
2
1, 2

(

)

(

)
(27)

)

where,
B (α , β ) =

Γ (α )Γ (β )
and
Γ (α + β )
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Γ (z ) −

∫0∞t z−1e −t dt or,

∫01 in( t1 ) z−1dt ,

for real (z ) > 0

are the Beta function and the Gamma function, respectively, and

p

Fq

{

a1, ………, ap ; u
b1, ………, bq

}

( )

∞ (a1) ………(ap )
k
k uk
= ∑
(
b
)
………(
b
)
k!
k =0 1
q

k

k

(29)

is the generalized Hypergeometric function.
For simplicity, we assume that the influence of growth factors do not affect the scaffold
dynamics. As such, we will use first order decay kinetics for scaffold degradation:31,36
d (Scaffold)
= − γ Scaffold
dt

(30)
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Finally, by assuming that cell–mass is constant (although this is not the case in reality as
described by Meaney Murray et al.20), then the mean total engineered cartilage construct mass
during steady state metabolism can be described by:

∫02z f z(z)dz

M ∞ = M Cell + ( K 1 + K 2)

+Limτ →∞(Scaffold)initiale

−k2τ

(31)
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In addition to the ECM carrying capacities, important parameters of the two probability models
within Model II (Eqs 20 and 21) are the growth rates of ECM molecules, λ1 and λ2, and the
levels the growth factor with respect to matrix molecule synthesis, ℜ1 and ℜ2. Wilson et al.
substituted λi , (where i = 1, 2 for GAG and collagen) with one over a characteristic time
constant, χi (where i = 1, 2 for GAG and collagen), and defined its value via a model fitting
technique.36 Similarly, the growth fctor levels, ℜi (where i = 1, 2 for GAG and collagen) are
input parameters which can be experimentally observed to achieve steady state metabolism,
13 or adjusted within the mathematical model to guide construct design, as will be done here.
Experimental results of matrix molecule accumulation have been reported by others and are
shown in Table 1. These data were used as input for the presented mathematical model
simulation.

COMPUTER SIMULATION RESULTS
For the numerical analysis based on the mathematical model where growth factor effects are
not directly manipulated (Model I), the GAG molecule growth rate, λ1, was approximated by
1/χ1 (Table 1). The numerical solution of GAG accumulation (dimensionless form) with respect
to time (dimensionless form) was determined (Fig. 1). Accumulation curves over time were
obtained by estimating the parameter λ1 from experimental data reported by Buschmann et al.
4 and Wilson et al.36 Qualitatively, the numerical solutions of GAG accumulation were similar
to that of the experimental data points from which the model was based.4,36
The numerical solution of collagen accumulation (dimensionless form) with respect to time
(dimensionless form) without direct growth factor manipulation was determined (Fig. 2). The
Ann Biomed Eng. Author manuscript; available in PMC 2006 March 17.
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accumulation curves were obtained by estimating the collagen growth rate parameter λ2 from
experimental data reported by Wilson et al.36 and Ragan et al.29 The numerical solution of
collagen accumulation was qualitatively similar to the experimental results from Wilson et al.
36 but does not match with the Ragan et al.29 data.
For Model II, which modified Model I to include growth factor variability, the steady state
probability density functions of GAG and collagen molecules incorporated in equations (20)
and (21) were determined (Figs. 3 and 4). These results indicate how the potential stochastic
environment would affect ECM synthesis on a local level. Additionally, the computational
results indicated the following features in engineered cartilage constructs dynamics: First, the
effect of growth factor was not necessarily the same on both the matrix molecules. Utilizing
experimental data on engineered cartilage accumulation,36 the simulated level of growth factor
for GAG synthesis varied within the interval 0.004 < ℜ1 < 0.099, whereas for collagen
molecules, the level term varied, 0.02 < ℜ2 < 0.316. The regulatory effects due to different
types of mediator molecules, such as decorin and biglycan with dermatan sulfate chains, and
fibromodulin with keratan sulfate chains may be primarily responsible for this but were not
modeled.
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Second, both inhibition and stimulation of total matrix deposition within the construct were
entirely dependent upon the level of growth factor within the simulated construct. The
numerical outcome of the total matrix molecule deposition (GAG + Collagen) in the steady
state was determined (Fig. 5) on the basis of the parametric values given in Table 1. From the
simulation, when the combined effects of the growth factor (ℜ1 + ℜ2) were less than a threshold
value of ~0.2, then the overall matrix molecule deposition in the steady state was higher than
its deterministic counterpart (i.e., Model I). In that case, the combined effects of growth factor
stimulate the overall deposition of matrix molecules within the construct. Alternatively, when
the growth factor state (ℜ1 + ℜ2) was less than the thresh-old value, additional growth factors
appeared to inhibit the deposition of matrix molecules.

DISCUSSION
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It is well-known from experimental reports that growth factors have some effect on the
dynamics of Cell–polymer constructs. Investigators have made great strides in deciphering the
sophisticated signal transduction processes triggered by application of a growth factor to a cell,
or engagement of a receptor by a growth factor. These discoveries have not all been reduced
to definitive mechanistic models for tissue engineering. Experimentalists are still exploring
growth mechanisms in native and engineering tissues via controlled methods, resulting in a
few definitive conclusions. As potential insight to this complex issue, this study incorporates
the effects of growth factor dynamics as a stochastic fluctuation into the system’s environment
and examines the effects on the overall composition.
Although the numerical analysis simulating ECM synthesis in Model I was driven toward a
deterministic state based on experimental steady state conditions, the dynamic influence of
growth factors was only explored in Model II. Nonaggregating proteoglycans such as decorin,
biglycan and fibromodulin are common in all cartilage tissue. These small molecules interact
with collagen fibrils and regulate transforming growth factor β’s (TGF-β) activities by
sequestering it within the ECM.16 It has been reported by several other researchers that these
small proteoglycan molecules are responsible for regulating the activities of TGF-β within the
ECM.15,19,23,34 Although, the exact mechanisms of how the growth factors release its effects
on the matrix molecules are not clear, there is evidence that the functional activity of the growth
factor increases as matrix molecule concentration increases. On the basis of this hypothesis, a
monotonic increasing function of matrix molecules (Model I) was modified with a function
involving randomized effects of additional growth factor (Model II).

Ann Biomed Eng. Author manuscript; available in PMC 2006 March 17.
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Working principles of ECM metabolism within the cartilage Cell–polymer constructs are not
fully known. Researchers understand that growth factors and cytokines have strong anabolic
and catabolic influences, respectively, on the dynamics of matrix molecules. However,
deterministic physiological laws have not yet been identified. From a mathematical point of
view, the effects of growth factors in the presented system dynamics were considered
randomised (via Gaussian white noise) and the ECM components independent in the cellular
environment. It has been reported that synthesis of collagen and proteoglycans by chondrocytes
are dependent upon the state of the surrounding matrix and respond uniquely if that matrix is
absent.12,26 Our results indicate that an inhibition or stimulation of matrix molecules
deposition may be modeled as dependent upon the initial application of growth factor within
the system. In a recent growth model of native cartilage explants,18 residual stresses were
considered which describe a compressive state within the proteoglycans because of the
increased fixed charge density while being balanced against a tensile stress supported by the
collagen network. This result offers insight for in vivo developmental cartilage growth
(chondrocytes surrounded by their own matrix), however, cell-seeded constructs may not have
the same mechanical boundary constraints or functional cultured time frame because of varying
seeding densities, cell adhesions, scaffold porosities, transport phenomena, and culture states.
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Relevant comparisons between the mathematical outcomes shown here and published
experimental findings examining growth factor influences are available. Pei et al. reported
from their experimental work on in vitro generation of cartilaginous constructs, that the
combination of growth factors TGF-β1 and FGF-2, applied sequentially from day 3 to day 10,
inhibits the collagen and GAG accumulation in ECM deposition remarkably.28 Additional
evidence of this inhibition was reported by Horton et al.17 Meaney Murray et al. reported from
their experimental work on human anterior cruciate ligament cells that the growth factors TGFβ1 and PDFG-AB (platelet derived growth factor) have a significant role in enhancing the
production rate of collagen.20 Finally, it has been reported by Weiser et al. that the production
of proteoglycan was significantly hampered under the influence of PDGF-BB.35 In nonconnective tissue, low doses of brain-derived neurotrophic factor, BDNF (0.5 to 2 μg/day for
28 days), which includes nerve growth factor, NGF, and neurotrophin, NT, promoted axonal
regeneration after axotomy.2 While high doses of BDNF (12 to 20 μg/day for 28 days)
significantly inhibited motor axonal regeneration after immediate nerve repair. Thus the
presented model may offer a predictive tool for the reported transition phenomenon from
promotion to inhibition during guided ECM synthesis.
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A question that arises from this work is whether growth factors alter the overall construct mass
in the steady state. By design, the mathematical approach described in Model I (Eq 10) drives
the construct to a final, deterministic state because of a presumed growth factor precondition
that has established steady state metabolism. This phenomenon was described experimentally
when 20 ng/ml of insulin-like growth factor maintained a steady state condition in proteoglycan
concentration.13 However, Model II (Eq 31) alters the dynamics in the final state of Model I
by providing a mathematical means for probabilistic steady state end points in the construct
design. Actual steady state mass of the total composite may be static if growth factors act as
an inhibitor of a particular type of matrix molecule while activating or enhancing the production
of other ECM molecules in addition to promoting or enhancing chondrocyte proliferation. As
such, a long-term balance may be maintained and overall construct mass may be regulated
through a suggested product inhibition machanism.13,36 Of course, neotissue synthesis and
scaffold degradation would require guided dynamics during the early stages of development
through time points leading to steady state. This time dependency is incorporated in both
developing constructs: Model I (with deterministic endpoints in equations 8 and 9) and Model
II (with probabilistic endpoints in equations 20 and 21). An additional level of mathematical
complexity would incorporate growth factor dependencies into the ECMss and carrying
capacity endpoints as empirically reported by Hascall et al.13
Ann Biomed Eng. Author manuscript; available in PMC 2006 March 17.
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The computer simulations show that the effects of growth factors as a probabilistic ECM
distribution, controlled the steady state total GAG and collagen accumulations whether through
stimulation or inhibition. For lower amounts of growth factor, an increase in collagen and GAG
accumulation was noted in comparison with the steady state value derived without accounting
for additional growth factor influence. In addition, excessive amounts of growth factor may
inhibit the steady state deposition of collagen and GAG molecules. Finally, only steady state
analysis was described in this paper. Long-term, transient analysis of the above system is under
construction.
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FIGURE 1.

Numerical solution of GAG accumulation in an engineered cartilage construct without growth
factor variability (Model I Eq 8). The top curve (dash line) was obtained by approximating the
growth rate as λ1 = 0.0584 (estimated from the data reported by Buschmann et al.4) and the
bottom curve (dash–dot line) has been obtained by approximating λ1 = 0.005 (estimated from
the data reported by Wilson et al.36). Here k is the carrying capacity of the GAG molecules in
engineered cartilage constructs (noted as K1 in the text).
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FIGURE 2.

Numerical solution of collagen deposition in an engineered cartilage construct (Model I Eq.
9). The bottom curve (dash line) has been obtained by approximating the growth rate λ2 =
0.0446 (estimated from the data reported by Ragan et al.29) and the top curve (dash–dot line)
has been obtained by approximating λ2 = 0.0529 (estimated from the data reported by Wilson
et al.36). Again, k is the carrying capacity of the collagen molecules in engineered cartilage
constructs (noted as K2 in the text).

NIH-PA Author Manuscript
Ann Biomed Eng. Author manuscript; available in PMC 2006 March 17.

Saha et al.

Page 14

NIH-PA Author Manuscript
FIGURE 3.

The steady state probability density function for GAG accumulation as a fraction of construct
carrying capacity under the simulated variability of growth factor (described by equation 20),
where λ1 = 1/187,36 and ℜ1 = 0.05.
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FIGURE 4.

The steady state probability density function for collagen deposition as a fraction of construct
carrying capacity under the simulated variability of growth factor (described by equation 21),
where λ2 = 1/18.9,36 and ℜ2 = 0.2.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Ann Biomed Eng. Author manuscript; available in PMC 2006 March 17.

Saha et al.

Page 16

NIH-PA Author Manuscript
NIH-PA Author Manuscript

FIGURE 5.

A plot demonstrating the simulated deposition of GAG plus collagen molecules in the steady
state condition (τ → ∞) due to a perturbation in growth factors. The abscissa indicates the leve
of growth factors (ℜ1 + ℜ2) and the ordinate represents the deposition of matrix molecules as
a coefficient of the carrying capacities (K1 + K2). The solid horizontal line in the middle of the
plot represents the total ECM accumulation where the variability of growth factor was not
extended beyond that achieving a fixed, steady state condition (outcome of Model I). Data
points are mean ECM accumulation (±5% of the combined probable distributions) for possible
steady state conditions when made dependent upon different levels of additional growth factor
(outcome of Model II). The curve represents the line of best fit. The model parameters were
chosen from the experimental data of Table 1.36
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TABLE 1

A subset of published matrix accumulation, modeling parameters,36 applied to the deterministic and stochastic models.

Agarose
Alginate
PGA/PLA
PGA/PLA

Cell type
BAC
BAC
BAC
BAC

Reference
Buschmann et al. (1992)
Ragan et al. (2000)
Wilson et al. (2002)
Wilson et al. (2002)

GAGss
17.2 mg/ml

Collagenss

15.7 μg/μg DNA

6.1% dw
6.5% dw

χ (days)
17.1
22.4
187
18.9

Saha et al.

Scaffold

Note. BAC = Bovine articular cartilage; PGA = Polyglycolic acid; PLA = Polylactic acid.
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